NYSE: FMSFresenius Medical Care Ag Stock
$28.32-0.45 (-1.56%)
Updated Jul 2, 2025
FMS Price
$28.32
Fair Value Price
N/A
Market Cap
$16.62B
52 Week Low
$17.93
52 Week High
$30.46
P/E
23.62x
P/B
1.02x
P/S
0.69x
PEG
0.8x
Dividend Yield
N/A
Revenue
$22.15B
Earnings
$671.93M
Gross Margin
24.5%
Operating Margin
6.95%
Profit Margin
3.2%
Debt to Equity
1.2
Operating Cash Flow
$3B
Beta
0.5
Next Earnings
Aug 5, 2025
Ex-Dividend
N/A
Next Dividend
N/A
FMS Overview
Fresenius Medical Care AG & Co. provides kidney dialysis services through its network of outpatient dialysis centers. The company also manufactures a variety of health care products, including dialysis and non-dialysis products. Fresenius was founded in 1996. Its global headquarters is in Bad Homburg vor der Höhe, Germany, and its North American headquarters is in Waltham, MA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine FMS's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Care Facility
Industry Rating
B
FMS
Ranked#27 of 42
Ranked#27 of 42
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $7.71 | A | |
| $14.94 | A | |
| $13.78 | A |
Be the first to know about important FMS news, forecast changes, insider trades & much more!
FMS News
Overview
Due Diligence Score
–
Industry Average (29)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how FMS scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
FMS ($28.32) is trading above its intrinsic value of $19.43, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
FMS is good value based on its earnings relative to its share price (23.62x), compared to the US market average (31.27x)
P/E vs Market Valuation
FMS is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more FMS due diligence checks available for Premium users.
Valuation
FMS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
23.62x
Industry
16.28x
Market
31.27x
FMS is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
FMS is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
FMS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.02x
Industry
4.6x
FMS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
FMS price to earnings growth (PEG)
For valuing profitable companies with growth potential
FMS is good value based... subscribe to Premium to read more.
PEG Value Valuation
FMS's financial health
Profit margin
Revenue
$5.3B
Net Income
$164.4M
Profit Margin
3.1%
FMS's Earnings (EBIT) of $1.54B... subscribe to Premium to read more.
Interest Coverage Financials
FMS's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$35.6B
Liabilities
$18.7B
Debt to equity
1.2
FMS's short-term assets ($9.04B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
FMS's long-term liabilities ($13.39B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
FMS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
FMS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$177.0M
Investing
-$117.7M
Financing
-$150.9M
FMS's operating cash flow ($2.75B)... subscribe to Premium to read more.
Debt Coverage Financials
FMS vs Medical Care Facility Stocks
Fresenius Medical Care Ag Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.